XBiotech Inc

4XB

Company Profile

  • Business description

    XBiotech Inc is a biopharmaceutical company that discovers and develops True Human monoclonal antibodies derived from human donors to replicate the human immune response in the treatment of various diseases. It has developed a pipeline of product candidates using True Human antibodies targeting both inflammatory and infectious diseases. The company's developement pipeline comprises: Natrunix, an antibody targeting IL-1a in oncology (pancreatic cancer), a clinical stage therapeutic for Methicillin Resistant Staphylococcus aureus (MRSA), and several pre-clinical stage therapeutics, including: an oral delivery antibody therapeutic for colon infection by C. difficile; an injectable therapy for varicella zoster (adult chicken pox), the causative agent for shingles; and an influenza therapy.

  • Contact

    5217 Winnebago Lane
    AustinTX78744
    USA

    T: +1 512 386-2900

    E: [email protected]

    http://www.xbiotech.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2026

    Employees

    87

Stocks News & Analysis

stocks

ASX healthcare share remains undervalued ahead of earnings

Margin recovery remains the key driver for this ASX healthcare share.
stocks

Alphabet earnings: Strong AI monetization continues to spearhead results

We maintain our fair value estimate for wide-moat Alphabet.
stocks

AMD: We’re pleased with Anthropic Partnership ahead of advancing AI event

We’re encouraged that AMD will count Anthropic as a third leading AI customer, in addition to OpenAI and Meta.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,941.5032.70-0.36%
CAC 408,372.280.000.00%
DAX 4025,099.00335.881.36%
Dow JONES (US)51,947.25235.600.46%
FTSE 10010,736.2397.060.91%
HKSE24,963.23247.58-0.98%
NASDAQ24,975.82161.87-0.64%
Nikkei 22564,611.151,811.45-2.73%
NZX 50 Index13,772.2923.02-0.17%
S&P 5007,411.983.680.05%
S&P/ASX 2008,772.3023.40-0.27%
SSE Composite Index3,814.2062.58-1.61%

Market Movers